Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.59 |
| ▸ | VNN1 | O95497 | 5/20 | 0.54 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.50 |
| ▸ | BTD | P43251 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610584 | 0.87 | KAT6A (0.59) | GRM5KAT6AIRAK4GSK3B | |
| SCHEMBL3609644 | 0.87 | GRM5 (0.59) | GRM5VNN1 | |
| SCHEMBL13130248 | 0.80 | GRM5 (0.55) | GRM5KAT6AIRAK4GSK3B | |
| SCHEMBL28230502 | 0.79 | KAT6A (0.53) | GRM5KAT6AIRAK4GSK3B | |
| SCHEMBL3611579 | 0.78 | MEN1 (0.55) | GRM5VNN1KAT6A | |
| SCHEMBL3608476 | 0.78 | GRM5 (0.56) | GRM5VNN1KAT6A | |
| SCHEMBL3613882 | 0.78 | VNN1 (0.49) | GRM5VNN1KAT6AIRAK4 | |
| SCHEMBL1544700 | 0.77 | GSK3B (0.51) | GRM5VNN1KAT6AIRAK4GSK3B | |
| SCHEMBL28815665 | 0.76 | SMPD1 (0.58) | GRM5KAT6AIRAK4GSK3B | |
| SCHEMBL29865489 | 0.76 | SMPD1 (0.58) | GRM5KAT6AIRAK4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029685-A1 | OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029685-A1 | OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA3, CHRNA5, CHRNB3 | GRM5 154/4885VNN1 1390/4885KAT6A 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.